A study found that less than 2% of 406 major drug-drug interactions were listed in all four national drug compendia and 71% were listed in only one of the expert sources.
How Mark Cuban Cost Plus Drug Company Is Approaching Drug Pricing Transparency
October 14th 2024Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.